Sunday, September 26

EANO Meeting - Sunday, September 26, 2021

All times below refer to Central European Summer Time (CEST).

09:00-10:30 hrs

Chairs: Anna Berghoff, Jan-Michael Werner

OS04.1 New therapies under investigation: What is TG02?
Emilie Le Rhun, France

OS04.2 Targets in Neuro-Oncology - What should we investigate next?
Simone Niclou, Luxembourg

OS04.3 New therapies under investigation: What is Marizomib?
Patrick Roth, Switzerland

OS04.4 Pitfalls in clinical trials design
Michael Weller, Switzerland

09:30-10:30 hrs

Chairs: Claudia Panciroli, Manuel Valiente

Presentations tba

Chairs: Antonella Castellano, Marilena Theodorou

ME03.1 Heterogenity and microstructure models with diffusion MRI
Eleftheria Panagiotaki, United Kingdom

ME03.2 Experimental new imaging in brain metastasis and translation to patients

Fabien Boux, France

ME03.3 Radiomics and AI in brain tumor imaging
Philipp Vollmuth, Germany

10:30-11:00 hrs | BREAK

11:00-12:30 hrs

Chairs: Emilie Le Rhun, Susan Short

Presentations tba

Chairs: Mihaela Lorger, Michael Weller

Presentations tba

Chairs: Djaina Satoer, Martin Klein

OS07.1 Functional Ultrasound: the new gold standard to measure language functions during awake brain surgery?
Ellen Collée, Netherlands 

OS07.2 Trial results of ReMind: the app for cognition rehabilitiation in primary brain tumor patients
Karin Gehring, Netherlands

OS07.3 Ready, Set, Shift: intraoperative mapping of concept-shifting improves outcome
Emmanuel Mandonnet, France

OS07.4 Guess where? Mapping the cognitive interface via invasive and non-invasive imaging techniques
Constanza Papagno, Italy

12:30-13:00 hrs | BREAK

12:30-14:45 hrs

EANO Youngsters Networking Event

13:00-14:00 hrs

Corporate Symposia

14:00-14:45 hrs

E-Poster Viewing with authors

14:45-15:00 hrs | BREAK

15:00-16:00 hrs

Chairs: Patrick Roth, Manuel Valiente

PC01.1 BBB/BTB in brain tumors (Maintained)
Patricia Steeg, United States

PC01.2 Compromised blood-brain-barrier
Patrick Wen, United States

Chairs: Iris Verploegh, George Petrescu

WS03.1 How to plan your career in neuro-oncology: Neurosurgery
Marike Broekman, Netherlands

WS03.2 How to plan your career in neuro-oncology: Neuroradiology
Antonella Castellano, Italy

WS03.3 How to plan your career in neuro-oncology: Basic/Translational Research
Pim French, Netherlands

WS03.4 How to plan your career in neuro-oncology: Computational Imaging Research
Georg Langs, Austria

WS03.5 How to plan your career in neuro-oncology: Pediatric neuro-oncology
Sabine Müller, United States

WS03.6 How to plan your career in neuro-oncology: Clinical neuro-oncology
Roberta Rudà, Italy

Chairs: Simone Niclou, Felix Sahm

WS04.1 Atlas of spatially resolved multiomics in malignant brain tumours
Dieter Henrik Heiland, Germany

WS04.2 scRNAseq and progenitor diversity in glioma
Q. Richard Lu, United States

16:00-16:30 hrs | BREAK

16:30-18:00 hrs

Chairs: Roberta Rudà, Wolfgang Wick

KS02.1 A novel prognostic and predictive DNA repair gene expression signature in glioblastoma
Mary-Helen Barcellos-Hoff, United States

KS02.2 DNA repair vulnerabilities in IDH mutant gliomas
Ranjit Bindra, United States

KS02.3 Clinical trials targeting the DNA damage response in glioma
Anthony Chalmers, United Kingdom

Chairs: Oliver Hanemann, Tobias Weiss

OS08.1 MR Spectroscopy for brain glioma diagnosis and therapeutic assessment
Francesca Branzoli, France

OS08.2 Integrated intraoperative diagnosis of brain tumors
Daniel Orringer, United States

OS08.3 Proteomics for brain tumor diagnosis
Andreas von Deimling, Germany

Chairs: Jérôme Honnorat, Riccardo Soffietti

JS05.1 Sex-based differences in Neuro-Oncology
Jill Barnholtz-Sloan, United States

JS05.2 Phase 0 and Window-of-Opportunity Trials in Neuro-Oncology
Susan Chang, United States

JS05.3 Discovery of tumor-reactive T cells in Neuro-Oncology
Michael Platten, Germany

JS05.4 Circulating Tumor DNA in Neuro-Oncology
Joan Seoane, Spain

18:00-18:30 hrs | BREAK

18:30-19:30 hrs

Chairs: Karin Piil, Kathy Oliver

ME04.1 What can the wider community learn from people living with brain cancer during COVID?
Helen Bulbeck, United Kingdom

ME04.2 The Brain Tumour Patients’ Charter of Rights
Kathy Oliver, United Kingdom

ME04.3 Brain tumours and COVID-19: the patient and caregiver experience
Mathew Voisin, Canada

Chairs: Elizabeth Cohen-Moyal, Manuel Valiente

ME05.1 Clinical implications of brain metastasis heterogeneity
Priscilla Brastianos, United States

ME05.2 Mouse models of glioma heterogeneity
Dolores Hambardzumyan, United States

ME05.3 Dissecting response to treatment in adult patients with a glioma
Roel Verhaak, United States

Chairs: Anna Golebiewska, Tobias Weiss

ME06.1 Organotypic brain tumor cultures
Simone Niclou, Luxembourg

ME06.2 3D-bioprinted models of brain tumors
Ronit Satchi-Fainaro, Israel

ME06.3 A patient-derived glioblastoma organoid model recapitulates inter- and intra-tumoral heterogeneity
Hongjun Song, United States

Note that the programme is subject to change and will be continuously updated.